In this modified intention-to-treat population , asthma symptoms did not get clinically significantly worse ( mean change in six-item Asthma Control Questionnaire < @ ) and IFN - treatment had no significant effect on this primary endpoint , although it enhanced morning peak expiratory flow recovery ( P = @ ) , reduced the need for additional treatment , and boosted innate immunity as assessed by blood and sputum biomarkers .